edical or veterinary science and hygiene (A61)

A   Human necessities(312083)
A61            edical or veterinary science; hygiene(132510)

Liposomal suspensions stabiliser // 2642786
FIELD: pharmacology.SUBSTANCE: conjugate of the invention is a compound of formula (C6O4H9NH2)m(C6O4H9NHX)n, wherein the remainder of the polyethylene glycol derivative, which is a monomethoxy-PEG succinate acts as a substituent on the amino group X, the molecular weight of chitosan used to prepare the conjugate is 15 to 120,000 daltons, am and n are the number of units in the molecule, where m/n is 6 to 19. The proposed method involves preparation of a solution of N-hydroxysuccinimide ester of PEG-hemisuccinate in dimethylformamide or dimethylsulfoxide, mixing of the solution prepared with an acidic solution of chitosan with a molecular weight of 15-120 kDa, and adjustment of the resulting mixture to a pH of 7.5-8.0, followed by purification by dialysis against buffer solution.EFFECT: new substance effective for liposomal suspensions stabilization is disclosed, and an effective method for its preparation.3 cl, 3 dwg, 4 ex

Fluorine-9-methyl-β-carbolines // 2642785
FIELD: pharmacology.SUBSTANCE: invention relates to a compound of the general formula (I) , where R1 is -F, and R2 is -H or -F, or R1 is -H, and R2 is -F; which can be used as a medicine for treatment of diseases and/or injuries of the inner ear.EFFECT: increased efficiency of compounds.10 cl, 30 dwg, 1 tbl, 9 ex
Forzicyaside sulfate and its derivatives, method for its production and its application // 2642784
FIELD: pharmacology.SUBSTANCE: invention relates to forzicyaside sulfate and its derivative represented by the following formula , wherein R is Na+, K+ or NH+, and a method for their preparation, as well as an antiviral drug based on them and its use.EFFECT: increased efficiency of agents.10 cl, 9 tbl, 2 dwg
New benzoazepine derivative and its medical application // 2642783
FIELD: pharmacology.SUBSTANCE: invention relates to a new benzoazepine derivative of formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents a hydroxyl group, a lower alkoxy group or , where A is absent or a lower alkylene group which may be substituted by a lower alkyl group; R6 represents a hydrogen atom or a lower alkyl group; R7 represents a hydrogen atom, a hydroxyl group, a five-membered aromatic heterocyclic group containing 3 heteroatoms selected from nitrogen and oxygen which may be substituted by a lower alkyl group, a five-membered non-aromatic heterocyclic group containing one nitrogen atom which may be substituted by an oxo group or a carbamoyl group , which may be substituted by a lower alkyl group; R2 represents a hydrogen atom or a lower alkyl group; R3 is a lower alkyl group which may be substituted by 1 to 3 fluorine atoms or a halogen atom; R4 represents a lower alkoxy group which may be substituted by 1 to 3 halogen atoms, a five-membered aromatic monocyclic heterocyclic group or a five-membered non-aromatic monocyclic heterocyclic group (provided that each of these heterocyclic groups contains one nitrogen atom, two nitrogen atoms or one nitrogen atom and one oxygen atom in the ring, and may contain a lower alkyl group); and R5 represents a hydrogen atom, a lower alkyl group or a halogen atom. The invention also relates to a pharmaceutical composition based on a compound of the formula and intermediates of the formulas and .EFFECT: new benzoazepine derivatives having V2 receptor agonist activity are obtained.14 cl, 12 tbl, 128 ex
Comt inhibitors // 2642779
FIELD: pharmacology.SUBSTANCE: invention relates to new compounds of the formula (I) and their pharmaceutically acceptable salts which have the properties of a catechol-O-methyltransferase (COMT) inhibitor. In the compound of the formula (I) , where R1 is hydrogen, methyl, Br, F or Cl; R2 is hydrogen, lower alkyl, Br, I, C3-6cycloalkyl, C(O)O-lower alkyl, C(O)NH-lower alkyl substituted by halogen, C(O)(morpholine) or is 3,4-dihydronaphthalen-2-yl optionally substituted by lower alkyl, 1,2,3,4-tetrahydronaphthalen-2-yl, 2,3-dihydrobenzofuran-6-yl, 1-methyl-2,3-dihydro-1H-indolin-5-yl, 1-methylindolin-5-yl, tetrahydropyran-4-yl, 3,6-dihydro-2H-pyran-4-yl, 2-isopropyl-1,2,3-tetrahydroisoquinolin-5-yl, 2,3-dihydro- dimethyl[1,4]dioxin-6-yl, benzo[1,3]-dioxol-5-yl, 1,2,3,4-tetrahydroisoquinolin-7-yl optionally substituted by lower alkyl, cyclohexenyl, morpholinyl, 4-methylpiperazinyl, naphthalen-1-yl, naphtalen-2-yl, or represents (CHR)n-phenyl optionally substituted by one to five substituents R4, where R4 is F, Cl, CN, CH2-CN, lower alkyl, hydroxy, lower alkyl, substituted hydroxy, lower alkoxy, (CH2)1.2-lower alkoxy, S-lower alkyl, (CH2)1.2-S-lower alkyl, -CH2)1.2-S (O)2-lower alkyl, -S(O)2-lower alkyl, -S(O)2-di-lower alkylamino, -S(O)2-piperidinyl, lower alkyl substituted by halogen, -N=N-phenyl, di-lower alkylamino, (CH2)1.2-di-lower alkylamino, (CH2)2-NH-lower alkyl, NHC(O)-lower alkyl, lower alkoxy substituted by halogen, CH(CH3) C(O)O-lower alkyl, O-phenyl, O-benzyl, phenyl, optionally substituted CF3, SF5, benzyl, C(O)-lower alkyl, C(O)-phenyl, C(O)-morpholinyl, C(O)-4-methylpiperazinyl, C(O)-di-oxothiomorpholinyl, C(O)-piperidinyl, optionally substituted by F, C(O)-NH-(CH2)2-morpholinyl, C(O)-NR-(CH2)2-NR2, C(O)-N-di-lower alkyl, CH2-O-(CH2)2-4-methylpiperazinyl, CH2-O-(CH2)2-di-alkylamino, CH2-O-(CH2)2-pyrrolidinyl, CH2-O-(CH2)2-morpholinyl, CH2-O-(CH2)2-piperidinyl optionally substituted by lower alkyl substituted by halogen or lower alkyl, (CH2)3,4-pyrrolidinyl, (CH2)2,3-di-lower alkylamino, morpholinyl, CH2-morpholinyl, CH2-piperazine substituted by lower alkyl, -S(O)2-piperazine substituted by lower alkyl, CH2-O-C(O)-piperazine substituted by lower alkyl, pyrazolyl or (CH2)1,2-lower alkoxy; R is hydrogen, lower alkyl or hydroxyl; n is 0, 1, 2, or 3; or R2 is C(O)-phenyl optionally substituted by lower alkyl; or is -O-phenyl optionally substituted by F; or is CH=CH-phenyl optionally substituted by lower alkyl; or is C≡C-phenyl; or R2 is a heteroaryl selected from the group consisting of pyrazolyl, thiazolyl, pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl, isothiazolyl, thiophenyl, 1-thia-3,4-diazolyl, imidazo[1,2-a]pyridinyl, indazolyl, quinolinyl or isoquinolinyl, and the said groups are optionally substituted by R5, where R5 is halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, hydroxy, (CH2)1.2-lower alkoxy, CH2-di-lower alkylamino, di-lower alkylamino, morpholinyl, piperazinyl, pyrrolidin-1-yl, C(O)-piperidinyl, C(O)-4-methylpiperazinyl, phenyl optionally substituted by halogen, pyridinyl, S(O)2N(CH3)2, C(O)O-lower alkyl, NHC(O)-lower alkyl, or is C(O)-heteroaryl selected from pyridinyl and thiophenyl, where heteroaryl groups are optionally substituted by lower alkyl, n is 0, 1, 2 or 3; R3 is hydrogen, methyl, Br, F, Cl, CF3, nitro, amino, cyano, NHC(O)-phenyl, or is 1-methyl-1,2,3,6-tetrahydropyridinyl, or is pyridinyl optionally substituted by methyl or morpholinyl, or is phenyl optionally substituted by methyl , SO2CH3, CF3, CN, F or C(O)N (di-lower alkyl).EFFECT: compounds can be used to treat Parkinson's disease, depression, cognitive impairment and motor symptoms, resistant depression, cognitive impairment, mood and negative symptoms of schizophrenia.16 cl, 2 tbl, 256 ex
2-aminopyrasine derivatives as csf-1r kinase inhibitors // 2642777
FIELD: pharmacology.SUBSTANCE: invention relates to a compound that is an amino acid or ester of an amino acid of formula , or a pharmaceutically acceptable salt thereof, which has an inhibitory activity against CSF-1R kinase. In formula (I), ring A is a phenyl group; R1 and R2 independently represent a hydrogen atom, a halogen atom or an unsubstituted C1-4 alkyl; n is 1; X is NH; V is -N=, W is -C(Z)=; Z represents a hydrogen atom, a fluorine atom, a chlorine atom or unsubstituted C1-3 alkyl; ring B is a 1,4-phenylene, 1,3-phenylene or pyridinyl group; [Linker] is a -(CH2)m-X1-(Alk1)x-Y1 group, where m is 0, 1, 2 or 3; x is 0 or 1; Alk1 is an unsubstituted C1-3 alkylene group; X1 and Y1 independently represent a bond, -O-, -S-, -NR7th-, -C(=O) - or -C(=O)NR5-, where R5 is a hydrogen atom or C1-4 alkyl and R7 is a hydrogen atom, unsubstituted C1-4 alkyl or -C(=O)CH3; R is a group of formula or , in which R8 is a -COOH group or an ester group of the formula -(C=O)OR14, where R14 is R15R16R17C-, where any R15 represents a hydrogen atom or C1-3alkyl-(Z1)a-[(C1-C3)alkyl]b-, where a and b are independently 0 or 1, Z1 is -O-, -S- or -NH-, R16 and R17 independently represent a hydrogen atom or C1-3 alkyl- or R15 and R16, taken together with the carbon atom to which they are attached, form a 3-7-membered cycloalkyl ring; and R17 represents a hydrogen atom; where (i) R9 and R10 are side chains of natural amino acids, (ii) one of R9 and R10 represents a hydrogen atom or unsubstituted C1-4 alkyl, and the other is an unsubstituted C1-6 alkyl group or C1-6 alkyl group substituted by a C1-4 alkoxy group, or (iii) R9 and R10, taken together with the carbon atom to which they are attached, form a saturated spiro-cyclobutyl ring; R11 represents a hydrogen atom or an unsubstituted C1-2alkyl group; ring D is a 5- to 7-membered saturated heterocyclyl group with at least one nitrogen atom in the ring. The invention also relates to a pharmaceutical composition, a method of treatment or prevention of diseases or disorders mediated by CSF-1R kinase, as well as application of the said compounds for preparation of a medicament useful for treatment of such diseases.EFFECT: increased application efficiency.18 cl, 59 ex
ethod for non-invasive pressure determination in lower cavopulmonary link in children with functionally single ventricle after total cavopulmonary link surgery // 2642748
FIELD: medicine.SUBSTANCE: peak linear speed of blood flow in the hepatic vein is determined in pulse-wave mode on exhalation (HV1) and inhalation (HV2), at a distance of 3-5 cm from hepatic vein confluence into the lower hollow vein. To do this, an ultrasonic system with a convex sensor is used, the control volume of which is 1/3 of the diameter of the middle hepatic vein, and the pressure value in the lower cavopulmonary link is determined by the original formula.EFFECT: method allows non-invasive monitoring of the pressure index in the lower cavopulmonary link in dynamics without additional preparation.1 ex

Device for single-moment bloodless adenomectomy // 2642741
FIELD: medicine.SUBSTANCE: device contains a tubular drill that is connected by its rear end to an electric drill and is an electro coagulator. Tissues cut with a drill with coagulated masses are sucked through the tube lumen and are delivered through the tap into a reticulated basket with volumetric divisions in the vacuum cylinder, where the completeness of adenomal tissues removal is determined by comparison with the preoperative volume of the adenoma.EFFECT: minimal damage to the anatomical structures and tissues of the area.1 dwg

Electronic-mechanical instrument for architectural reconfiguration of musculoskeletal system at ligamental and musculoskeletal level // 2642740
FIELD: medicine.SUBSTANCE: device to affect individual muscular parts of the Atlas-occipital articulation contains a hollow body, an electric mini-motor located in the body and a reduction gear that transfers reciprocating motion to the rod, and a tip with a head at the end. The head is rigidly fixed to the instrument body by a clamp and is designed to affect the upper oblique muscle, the anterior rectus muscle and then the lateral rectus muscle of the head from the left and right sides of the neck. A spiral groove of circular profile with metal balls located in it is made on the end part of the tip with a possibility of their movement when the tip rotates and the movement of the head is ensured. A through hole is provided on the tip, which ensures balls return to the initial turns of the spiral.EFFECT: invention allows to increase therapeutic effectiveness and quality of treatment of spine diseases by developing the most effective tool that allows to exert an effective effect on the muscles, that is, to reconfigure the musculoskeletal system on the ligamental and musculoskeletal level architecturally.1 dwg
ethod for surgical management of open-angle glaucoma in patients with pseudophakia // 2642731
FIELD: medicine.SUBSTANCE: for complex treatment of glaucoma with Ex-PRESS shunt, drainage "Glautex" is implanted under the superficial scleral flap over the shunt cap. A square flap of scleroplastic material with a size of 3×3 mm, and thickness, commensurate with the thickness of the superficial scleral flap is laid on a superficial scleral flap. A continuous suture is applied on the conjunctiva over the square flap of scleroplastic material.EFFECT: method improves the effectiveness of surgical treatment of secondary and primary open-angle glaucoma in patients with pseudophakia, by reducing postoperative complications such as teething and divergence of the conjunctival suture, reducing the risk of the metal Ex-PRESS shunt exposure in the long-term postoperative period, and achieving a prolonged hypotensive effect in the postoperative period.2 ex

Adaptive base plate of stoma device // 2642729
FIELD: medicine.SUBSTANCE: plate comprises a flexible top film and has at least the first and the second segment, at least the first skin-friendly elastic adhesive on the proximal surface of the flexible top film, and a receiving through hole for stoma in the said first segment. At that, the first segment adjoins the said through hole and extends radially therefrom. The said second segment surrounds the said first segment, and one or more security pads. At least the said first segment is reversible into the first substantially concave shape, and the said second segment has the second substantially convex shape that is reversible into a concave shape.EFFECT: facilitated access to the plate.13 cl, 7 dwg

Control of patient interface means fixation // 2642727
FIELD: medicine.SUBSTANCE: first version of the system contains a patient interface means to supply a gas stream to the patient. The interface means comprises a headband for securing to the patient and a mechanism for fixing force adjustment. The system includes a device for monitoring the degree of blood flow through the patient's blood vessel. The device contains a sensor and a control unit. The sensor detects the data on the blood flow through the blood vessel and is connected to the control unit to transfer the data to the control unit. The control unit is able to receive data from the sensor and to estimate the degree of blood flow based on the data mentioned. The control unit is able to provide a signal based on the blood flow in the blood vessel. The system comprises an adjusting mechanism controlling the force of patient interface means fixation by means of the headband, based on the signal provided by the detection device. In a second version of the system, the evaluation unit controls the audio signal generator to generate a warning signal if the degree of blood flow in the blood vessel or the degree of blood vessel occlusion passes a predetermined threshold. A warning signal indicates that the fixation force of the interface means is too strong. The force should be adapted by the adjusting mechanism. The method for prevention of red marks formation comprises the steps of interface means fixation to the patient by means of fixation force. The degree of blood flow through the patient's blood vessel is then assessed. Further, the fixation force is adjusted so that blood flow is present and that the blood flow exceeds a predetermined threshold.EFFECT: creation of a system and method that ensures reduction of red marks, and increased comfort of wearing of the patient interface means.15 cl, 5 dwg

agnetic-resonance visualization using acoustic radiation pressure power // 2642724
FIELD: physics.SUBSTANCE: device contains a magnetic-resonance imaging system for magnetic resonance data collection from the subject in the area of visualization, a system of focused high intensity ultrasound, a processor, wherein the execution of commands causes the processor to control the magnetic-resonance imaging system to collect magnetic resonance data using a pulse sequence. The pulse sequence contains a pulse imaging sequence using acoustic radiation force that contains an exciting pulse, a multi-dimensional gradient pulse applied during the radio frequency excitation of an area of interest which is two-dimensional, so the area of interest has a two-dimensional cross section. The two-dimensional cross-section has a rotational symmetry about the axis of the area of interest, wherein the axis of the area of interest and the axis of the beam are coaxial. The area of interest comprises a predetermined volume that encompasses the target zone and at least a portion of the beam axis. The processor also controls the system of focused high-intensity ultrasound for ultrasonic processing of the target zone so that the ultrasonic processing of the target zone occurred during the pulse imaging sequence using the acoustic radiation force and the image obtained using the impact force is reconstructed, using the magnetic-resonance imaging data. In a medical device operating using a computer-readable medium, a method of operating a medical device for magnetic-resonance imaging using the acoustic radiation force is performed.EFFECT: group of inventions allows to reduce the time of designing the image in real time.14 cl, 6 dwg

ethod for identification of patients with first attacks of acute porphyria // 2642723
FIELD: medicine.SUBSTANCE: clinical and laboratory criteria: gender, age - are determined. History data is determined: intake of new drugs, alcohol, newly diagnosed liver pathology, disease symptoms in the premenstrual period, emotional instability. The presence of tachycardia, arterial hypertension, dyskinesia of the gastrointestinal tract: constipation or diarrhea, nausea and vomiting, pain in the abdomen - are also determined. Presence of urine dark in daylight is identified. The presence of muscle weakness in the form of tetraparesis, paraparesis, hemiparesis is determined. The presence of a violation of urination and defecation control; violation of sensitivity are revealed as well, body temperature, appearance of hallucinations and delirium, epileptiform seizures are determined. The presence of dyspnea, facial nerve paresis, bulbar disorders is determined. The presence of leukocytosis of more than 12*109/l and ESR of more than 30 mm/h, bilirubinuria, erythrocyturia, excess reference values of uric acid, urea and hyponatremia are revealed as laboratory indicators. Clinical and laboratory criteria are scored in accordance with Table 1 contained in the description. The derived points are summed up. If the score is less than 5 - acute porphyria is unlikely, from 5 to 15 - porphyria is possible, more than 15 - acute porphyria is highly probable.EFFECT: method allows to effectively and quickly identify patients with acute porphyria due to comprehensive assessment of the most significant indicators.2 dwg, 3 tbl, 3 ex

Intervertebral disc endoprosthesis // 2642722
FIELD: medicine.SUBSTANCE: intervertebral disc endoprosthesis contains upper and lower axisymmetric and opposite supporting plates with serrated fixation elements in the bodies of the vertebrae on plates outer surfaces and elastic supporting-centering elements installed between them. The supporting plates are provided with annular beads on inner surfaces and located at different distances from the center by two concentric rows of holes located at the same angular distance from each other in staggered order. The supporting-centering elements are made in the form of V-shaped rod springs of round section with ends curved parallel to the supporting plates axes, embodied in their mirror located holes, vertices of springs, enshrined in holes of rows proximal to the plates axis are facing outwards, and distant - facing the axis, and placed accordingly in radial notches on the outer and inner forming cylindrical surfaces of the flat sprung-separation ring installed between the springs vertices. The cavity formed by the supporting plates is filled with bioinert elastoplastic material.EFFECT: simplified design by excluding movable joints with external friction, dimensional, mechanical wear-prone joints from the composition of its supporting-centering element, absence of wear debris falling into the human body tissues, and consequently, of the need to remove them during inspection, ensuring the stability of relative position elements of the implant, simplified manipulation for its installation, increased service life of the implant and reduced duration of surgery.3 dwg

System and method of selective illumination of baby during phototherapy // 2642682
FIELD: medicine.SUBSTANCE: system and method for selective illumination of (part of) a baby during phototherapy uses an array of collimators and a set of light sources to control electromagnetic radiation contact with the baby. Moreover, individual collimators include a reflective tube configured to direct electromagnetic radiation, and the set of light sources and the array of collimators are separated in space.EFFECT: group of inventions allows to selectively illuminate a part of the baby based on the position of the baby.18 cl, 3 dwg
ethod for increase of organism resistance to combined toxic action of nanoparticles of copper, zinc and lead oxides // 2642674
FIELD: medicine.SUBSTANCE: method for reduction of the adverse effects of combined effects of copper (CuO), zinc (ZnO) and lead (PbO) oxides nanoparticles on organism in risk groups covering individuals exposed to such effects under production conditions. Method includes prescription of a complex of biologically active drugs: glutaminic acid, glycine, N-acetylcysteine, pectin enterosorbent, fish oil preparation rich in unesterified omega-3 fatty acids, Vitamins A, C, D3, E, selenium, iron and iodized preparations. This complex is taken by repeated courses 1-2 times a year for 4-6 weeks daily at doses providing daily intake of 300 mg of glycine, 600 mg of cysteine, 4 g of glutaminic acid, 25 ml of fish oil with 12-15% content of polyunsaturated omega-3 fatty acids, 4-5 grams of pectin, as well as selenium, iron, iodine and these vitamins in doses that provide the normal physiological needs of the organism.EFFECT: reduction of all three metals in the blood, improved elimination function of the liver and kidneys, reduced integral signs of chronic intoxication, including signs of neurotoxicity, and genotoxic combined action of copper, zinc and lead oxides nanoparticles on the body.6 tbl
Composition for increasing operability and physical durability // 2642673
FIELD: food industry; pharmaceutical industry.SUBSTANCE: invention relates to the pharmaceutical and food industries and is a composition for improving working capacity and physical endurance comprising vitamin A, vitamin E and succinic acid, characterized in that it further comprises dry guarana extract and a chocolate mass, the components in the composition being in a certain ratio, in mass %.EFFECT: invention provides good taste qualities, a convenient form for reception, and also provides for a short time increase in efficiency and physical endurance by taking a complex of active substances optimally selected and in an amount sufficient to achieve maximum effect.1 cl, 3 ex, 2 tbl

Inhibitor of hyaluronic acid decomposition including rosemary extract and retinol acetate // 2642672
FIELD: pharmacology.SUBSTANCE: hyaluronidase inhibitor includes rosemary extract and retinol acetate in the following ratio: 0.01 - 5 wt % parts of retinol acetate per 1 wt % part of rosemary extract. Means for external use on the skin to alleviate or prevent skin problems selected from the group consisting of skin aging, wrinkled skin, rough skin, dry and rough skin, acne and atopic dermatitis, including a hyaluronidase inhibitor. The cosmetic treatment method includes rosemary extract and retinol acetate application to the subject suffering from a decrease in the hyaluronic acid level, in the following proportion: 0.01-5 wt parts of retinol acetate per 1 wt % part of rosemary extract.EFFECT: agent has a synergistic activity of hyaluronidase inhibition.3 cl, 1 dwg
Packaged product of solid preparation containing 5-hydroxy-1h-imidazole-4-carboxamide, or its salt, or its hydrate // 2642670
FIELD: medicine.SUBSTANCE: invention relates to a packaged product of a solid preparation containing 5-hydroxy-1H-imidazole-4-carboxamide or its salt, or its hydrate and a medium regulating agent, as well as a method for solid preparation stabilizing. The packaged product of the present invention is characterized by the colour differences of the solid preparation being no more than 3, when evaluating the solid preparation surface before and after storage for 3 months under conditions of 40°C and relative humidity of 75%, or for four weeks under conditions of 60°C.EFFECT: invention provides a packaged product of a solid preparation containing 5-hydroxy-1H-imidazole-4-carboxamide or its salt, or its hydrate, with excellent stability of solid preparation during storage.6 cl, 1 tbl, 15 ex
ethod for treatment of recurrent vulvovaginal candidiasis // 2642666
FIELD: medicine.SUBSTANCE: immunomodulatory therapy is administered by local action on the cervico-vaginal area with a drug containing sodium aminodihydrophthalazinedione, represented by the rectal suppositories Galavit, by introduction into the cervico-vaginal zone in successive doses of 100 mg overnight in three steps: the first preparatory phase of recovery of functional metabolic activity of cervical secret neutrophilic granulocytes by stimulation of their microbicidal activity by daily administration of the said drug with a course of 5 doses, one dose per day; the second stage of normalization of the monocyte-macrophagal system in the cervico-vaginal zone by enhancing phagocytosis using this drug with a course of 5 doses at a single dose with 48 hours pauses between them; the third stage of formation of a stable immune response in the cervico-vaginal zone at the local level by introduction of this drug with a course of 10 doses at a single dose with 72 hours pauses, and administration of a systemic antimycotic, which is itraconazole administered orally at a dose of 200 mg 1 dose daily, is performed at the third stage, starting with the administration of the 15th dose of Galavit.EFFECT: normalization of the local immune status, with preservation of a full-fledged immune response in the long-term period, a stable immunity is provided, with a reduction in the number of relapses and a reduction in the duration of treatment.3 cl, 2 tbl, 2 ex

Polymeric protein microparticles // 2642664
FIELD: pharmacology.SUBSTANCE: microparticles containing a core of therapeutic protein and a top layer of biocompatible and biodegradable polymer, and methods for production and application of these microparticles are proposed. The prolonged release of the therapeutic protein from the microparticles into saline is demonstrated over an extended period of time.EFFECT: group of inventions allows to expand the arsenal of available pharmaceuticals.18 cl, 3 dwg, 7 tbl, 9 ex

Compositions of long-term action insulins // 2642662
FIELD: pharmacology.SUBSTANCE: group of inventions refers to an aqueous pharmaceutical composition containing 270-330 U/ml of glargine insulin [equimolar to 270-330 IU of human insulin], wherein the composition containing 300 U/ml of glargine insulin is excluded, for treatment of type I and II diabetes.EFFECT: application of these inventions allows to provide a basal insulin reserve within 24 hours after a subcutaneous injection of a single dose.16 cl, 9 dwg, 12 tbl, 18 ex
ethods and systems for monitoring the power balance at flow and temperature disturbances at the product supply stage // 2642656
FIELD: packaging industry.SUBSTANCE: temperature changes minimization method of the completed product in the aseptic sterilisation processes involves using the power balance preventive control scheme as applied to the aseptic sterilisation process, wherein the power balance preventive control scheme comprises the preventive controller, that takes into account, as the input variables, the product density and heat capacity, calculated on the basis of the power balance principles for heating unit, in combination with the adjustment, calculated by the temperature control unit with feedback. The group of inventions also relates to the production process of the aseptic product, comprising the changes minimization in temperature of the finished product by the above mentioned method.EFFECT: group of inventions prevents the finished product damage from the occurring responses of heaters and coolers to the negative sudden temperature changes during the aseptic sterilisation process.15 cl, 4 dwg, 3 ex
Tint dye for hair on foaming basis // 2642655
FIELD: cosmetology.SUBSTANCE: dye includes henna, or colourless henna, or basma, or their mixture in an amount of 0.1-55 wt % as a filler; propylene glycol, glycerine, or their mixture in an amonur of 0.1-30 wt % as a solvent; a mixture of DEA cocaminde, betaine cocoamidopropyl, sodium lauryl ether sulphate, sodium lauryl sarkosinate, sodium cocosulfate, ammonium lauryl sarkosinate in an amount of 0.1-10 wt % as surfactants; direct non-ionic nitro dyes, main direct cationic dyes, acidic direct anionic dyes or their mixture in an amount of 0.1-7 wt % as a dye; preservatives in an amount of 0.1-1 wt %; functional additives in an amount of 0.1-10 wt % and water in an amount up to 100 wt %.EFFECT: homogeneous and uniform colouring, shading of grey hair.3 cl, 6 ex

Concentrated therapeutic phospholipide compositions // 2642653
FIELD: pharmacology.SUBSTANCE: composition for treatment or prevention of cardiometabolic disorders, a metabolic syndrome, neurodegenerative disorders comprises a concentrated therapeutic phospholipid extract comprising compounds of Formula I wherein the total amount of the phospholipid compounds of Formula I from the extract is in a concentration of 60 wt % to 90 wt % of the total weight of the composition and the extract includes astaxanthin; to a capsule containing a concentrated therapeutic extract of krill oil that contains the phospholipid compounds of Formula I and the extract includes astaxanthin; to application of a composition that includes a concentrated therapeutic phospholipid extract containing compounds of Formula I for preparation of therapeutic compositions for serum triglyceride levels lowering; to application of a concentrated therapeutic phospholipid extract that contains compounds of Formula I for preparation of pharmaceutical compositions for treatment of cardiovascular diseases.EFFECT: increased mass percentage of phospholipids in the composition.20 cl, 35 dwg, 2 tbl, 7 ex

Cosmetic application of harungana madagascariensis extract // 2642652
FIELD: cosmetology.SUBSTANCE: invention relates to cosmetology and is application of a cosmetic composition containing at least an aqueous extract of Harungana madagascariensis leaves and one or more formulation agents or additives selected from emollients, dyes, film formers, surfactants, fragrances, preservatives, emulsifiers, oils, glycols, UV filters and vitamins, to enhance collagen synthesis.EFFECT: invention protects the skin from aging, promotes collagen synthesis and protects skin proteins against glycation.7 cl, 2 dwg
Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cells factors, c3a/s4a complement proteins, immunoglobulins and chemotactic factors // 2642650
FIELD: pharmacology.SUBSTANCE: combination of cytokines, growth factors, chemotactic factors, stem cell factors, protein complement, immunoglobulins and antibacterial/antiviral factors, taken in a specific ratio and with a specific components composition for treatment of diseases, requiring reconstruction and regeneration of tissues. A pharmaceutical composition for treatment of diseases requiring restoration and regeneration of tissues.EFFECT: combination described above and the pharmaceutical composition can effectively regenerate and restore tissues.9 cl, 2 dwg, 11 tbl, 9 ex
ethod of treating inflammatory periodontal and oral mucosal diseases // 2642648
FIELD: medicine.SUBSTANCE: method of treating inflammatory periodontal and oral mucosal diseases include the elimination of acute and inflammatory processes in the acute stage, elimination of supragingival and subgingival dental deposits, surgical and orthopedic intervention if there is evidence; oral irrigation with ozonated mineral water, optionally hydromassage, irrigation, instillation and irrigation on disease sites of periodontal tissue and oral mucosa is held with 3.5-2.5% solution of bentonite in warmed up to 38-42° C ozonized mineral water for 15-30 minutes daily for 10-14 days and it is taken inside twice a day in small sips to 100-150 ml for 14-21 days. Mineral water is used as mineral water, having the following composition: total mineralization - 1.9-2.5 g/dm3, hydrogen carbonate ions - 740-950 mg/dm3, sulfate ions - 90-140 mg/dm3, chloride ions - 500-600 mg/dm3, calcium ions - no more than 15 mg/dm3; magnesium ions - no more than 10 mg/dm3; ions of sodium and potassium - 600-800 mg/dm3, strontium - no more than 25.00 mg/dm3, chromium - not more than 0.50 mg/dm3, zinc - no more than 5.00 mg/dm3, lead - no more than 0.10 mg/dm3, mercury - not more than 0.02 mg/dm3, selenium - not more than 0.05 mg/dm3, vanadium - no more than 0.40 mg/dm3, copper - not more than 1.00 mg/dm3, cadmium - not more than 0.01 mg/dm3, nitrates - not more than 50.00 mg/dm3, nitrites - not more than 2.00 mg/dm3, fluorine - not more than 10.00 mg/dm3, arsenic - no more than 1.50 mg/dm3, phenols - not more than 0.10 mg/dm3, uranium - not more than 1.80 mg/dm3, radium - no more than 5.2×10-7 mg/dm3, organic substances in terms of carbon - 5.00-30.00 mg/dm3. In particular, mineral water can be used from the source of the resort of Saki, the Republic of Crimea, mineral water from the source of the resort of Loutraki, Greece, mineral water from the resort's source in Evpatoria, the Republic of Crimea. Montmorillonite clay Kudrinsky deposit, the Republic of Crimea can be used as bentonite.EFFECT: effective treatment, reducing the risk of recurrence of inflammatory periodontal diseases and conditions after invasive interventions of the oral mucosa.5 cl, 3 ex

Disposable system for sterile obtaining of lipids and nucleic acids particles // 2642640
FIELD: pharmacology.SUBSTANCE: group of inventions discloses a system for sterile obtaining of lipids and nucleic acids nanoparticles and method for sterile obtaining of lipids and nucleic acids nanoparticles.EFFECT: group of inventions allows to obtain uniform lipid and nucleic acid particles by simple steps, reproducible and under aseptic conditions, and can be used to deliver this class of therapeutic molecules to target cells.23 cl, 13 tbl, 7 ex, 1 dwg
Processing of fish population by lufenuron // 2642637
FIELD: veterinary medicine.SUBSTANCE: drug is applied by oral administration of daily doses of 1 lufenuron to 30 mg/kg of fish biomass within a period of 3 to 14 days, while the total number of lufenuron used during the specified interval of time is from 7 up to 350 mg/kg of fish biomass.EFFECT: invention is suitable for treating salmon and provides continued effective protection against sea lice in the sea.10 cl, 6 tbl, 2 ex

Improved synergic antidiabetic compositions // 2642633
FIELD: pharmacology.SUBSTANCE: composition comprising inulin with a degree of polymerization (DP) below about 25, and a sulfonylurea and/or a derivative thereof, or a combination thereof, wherein the composition is synergic when used to treat or delay the onset of type 2 diabetes, and wherein the composition contains 5 mg to 50 g of inulin and 0.5 mg to 2000 mg of sulfonylurea and/or a derivative thereof, or a combination thereof. A method for treatment or delaying of the onset of type 2 diabetes. A method for treatment of hyperglycemia associated with type 2 diabetes. A method for prevention of development or alleviation of a side effect in a subject having type 2 diabetes treated with sulfonylurea and/or a derivative thereof or a combination thereof, wherein the side effect arises or is aggravated by treatment with sulfonylurea and/or a derivative thereof or a combination thereof. A method for prevention of development or alleviation of a pathological condition in a subject having type 2 diabetes or hyperglycemia associated with type 2 diabetes. A method for treatment or delaying of the onset of type 2 diabetes or treatment of hyperglycemia in a subject with type 2 diabetes.EFFECT: composition is effective for treatment or delaying of the onset of type 2 diabetes and acts synergistically.22 cl, 13 dwg, 13 tbl, 12 ex
Composition for prevention or treatment of chronic obstructive pulmonary diseases containing monoacethyldiglycerol compounds as active ingredient // 2642631
FIELD: pharmacology.SUBSTANCE: compounds of this invention reduce the expression level of CXCL-1, TNF-α or MIP-2, and thus do not have the side effects of the currently used therapeutic agents for chronic obstructive pulmonary disease treatment, are non-toxic and have an excellent therapeutic effect, so that they can be useful as a composition for prevention, treatment and reduction of chronic obstructive pulmonary diseaseseverity.EFFECT: prevention of chronic obstructive pulmonary disease containing monoacetyl diacylglycerin as an active ingredient.10 cl, 6 ex, 8 tbl

Boron-containing small molecules as anti-inflammatory agents // 2642628
FIELD: pharmacology.SUBSTANCE: invention relates to application of 5-(4-cyanophenoxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaborol, or its pharmaceutically acceptable salts for manufacture of a drug to treat or prevent diseases associated with inflammation, selected from acne and lupus in humans.EFFECT: application of this substance allows to treat skin diseases associated with an autoimmune component.3 dwg, 20 ex

Compositions and methods for inhibition of cellular adhesion or direction of diagnostic or therapeutic agents to rgd binding sites // 2642625
FIELD: pharmacology.SUBSTANCE: group of inventions concerns a peptide containing the glycine-arginine-glycine-cysteic acid-threonine-proline sequence, which inhibits cell adhesion to RGD binding sites. A composition, and a method for vitreoretinal disease treatment, and a method for stimulation of vitreolysis, dilation of the vitreous or vitreoretinal detachment are also described.EFFECT: group of inventions provides treatment of retinal diseases or simplified removal of the vitreous body during vitrectomy.10 cl, 6 ex, 5 dwg, 2 tbl
Pharmaceutical composition // 2642624
FIELD: pharmacology.SUBSTANCE: version 1 of the composition contains maleate indacaterol in an amount of 20-1200 μg in combination with fluticasone furoate in an amount of 0.5-800 μg or ciclesonide in an amount of 20-800 μg, lactose and optionally one or more pharmaceutically acceptable excipients. Version 2 of the composition contains maleate indacaterol in an amount of 20-1200 μg in combination with fluticasone furoate in an amount of 0.5-800 μg and tiotropium in an amount of 2.25-30 μg, lactose and optionally one or more pharmaceutically acceptable excipients. The composition is in a form suitable for administration once a day.EFFECT: composition according to the invention simplifies the mode of drug administration in the treatment of respiratory, inflammatory or obstructive airway diseases.2 cl, 49 ex
Stable compositions containing metal ion // 2642620
FIELD: chemistry.SUBSTANCE: proposed oral care composition includes: a) one or more pyrophosphates, wherein the total concentration of pyrophosphates in the composition is from 0.9 wt % up to 1.1 wt % in terms of the composition weight; b) one or more thickening gums, wherein the total concentration of thickening gums in the composition is from 1.25 wt % to 1.6 wt % in terms of the composition weight; and c) a source of zinc ions, which is a mixture of zinc oxide and zinc citrate, the ratio of the amount of pyrophosphate to the amount of thickening gums is less than 0.8. It is also proposed to use a combination of one or more pyrophosphates with one or more thickening gums to reduce or prevent the phase separation in the oral care composition under subclauses 1-15.EFFECT: use of the above pyrophosphate combination with thickening gums provides improved stability of the composition with respect to phase separation while maintaining an acceptable taste and mouth feel when using a composition containing a source of zinc ions.16 cl, 2 tbl
Spray system for aerosol and non-aerosol products // 2642618
FIELD: technological processes.SUBSTANCE: system for air fresheners contained in aerosol containers and non-aerosol containers, each comprising a spray nozzle, includes a spray device and an adapter designed to be detachably attached to the relief surface of the spray device. The spray device comprises: an inner portion formed by a front cover, a back cover and a base; an actuator; a controller designed to drive the actuator; a selector switch configured to be positioned in the aerosol spray position and to the product spray position other than the aerosol; a relief surface designed to receive the aerosol container in the inner part of the spray device so that the actuator can contact with the nozzle for the sprayed aerosol. The adapter is designed to receive a non-aerosol container in the inner part of the spray device, so that the actuator can contact with the nozzle to spray the product different other than the aerosol.EFFECT: expansion of the functionality of the deodorization system by using a single system for both aerosol and non-aerosol containers without the need to remove or replace any spray elements.9 cl, 16 dwg
Complex preparation for treatment of acute and chronic otites of parasitary, bacterial and fungical origin in dogs, cats, fur-bearing animals and rabbits // 2642617
FIELD: veterinary science.SUBSTANCE: this invention relates to veterinary medicine and can be used in the treatment of acute and chronic otitis of parasitic, bacterial and fungal origin in dogs, cats, fur-bearing animals and rabbits. Complex preparation in the form of eardrops contains levofloxacin, clotrimazole, dexamethasone, moxidectin, and also targeted additives.EFFECT: invention provides 100 % therapeutic efficacy for parasitizing of ear mites and 98–100 % efficacy for otites of bacterial and/or fungal etiology.1 cl, 4 ex
Oral care composition // 2642614
FIELD: pharmacology.SUBSTANCE: oral care composition comprising an orally acceptable carrier, a fluoride ion representing amine fluoride and a buffer having pKa less than 7.0. The buffer contains an aqueous solution of an acid and a salt of this acid where the acid is selected from succinic acid, malic acid, and combinations thereof; pH of the composition for oral administration is 4.2-4.8; the composition has an acid number greater than 6; amine fluoride is olaflur (N-octadecyltrimethylenediamine-N,N,N'-tris(2-ethanol)dihydrofluoride). Methods for application of the above composition, namely the method for fluoride ions delivery to the mouth of a mammal, a method for reduction of cavities formation in the teeth of mammals and a method for teeth remineralization in a mammal. Composition contents comprising the buffer can counteract the buffering effect of saliva and maintain the pH of the composition at a slightly acidic level during composition application.EFFECT: improved absorption of fluoride from the composition in damages caused by caries, and increased remineralization potential compared to toothpastes corresponding to the current state of art in the field.14 cl, 3 tbl
Complexes based on chondroitin for cutaneous absorption // 2642612
FIELD: pharmacology.SUBSTANCE: invention is a transdermal delivery composition comprising non-covalent complexes between non-sulphated chondroitin having a molecular weight of 5 to 100 kDa determined by exclusion chromatography and active ingredients selected from diclofenac or its salts and ketorolac or its salts.EFFECT: invention provides passage through the stratum corneum of the skin, penetration into the epidermis, through the mucous membrane, as well as delayed release of the active components.4 cl, 11 tbl, 7 ex

Composition and method for treatment of eye disease assiciated with nucleic acids // 2642609
FIELD: medicine.SUBSTANCE: composition for treatment of dry eyes syndrome associated with nucleic acids, which develops as a result of nucleic acids formation/generation together with formation of eye mucoid films and/or biofilms, contains deoxyribonuclease I (DNAase I) and ophthalmologic auxiliary substance, and does not contain antibiotics. The composition is applied to the eye surface to remove the nucleic acid from the eye surface. Also, a method for treatment of the said dry eyes syndrome is provided, comprising administration of the said composition to the eye in an effective amount.EFFECT: application of the group of inventions improves treatment of the dry eyes syndrome associated with nucleic acids, which develops as a result of formation, generation of nucleic acids together with formation of eye mucoid films or biofilms.13 cl, 16 dwg, 7 ex

System delivery and regulated expression of paracrine genes for treatment of cardiovascular and other diseases // 2642605
FIELD: medicine.SUBSTANCE: group of inventions can be used to treat heart failure with congestive heart failure (CHF), diabetes or prediabetes in vivo in a patient in need thereof. To this end, a vector is administered to a subject comprising a nucleic acid encoding a paracrine polypeptide or a peptide selected from the group consisting of cardiotonic peptide, urocortin-2 (UCn-2), urocortin-1 (UCn-1), urocortin-3 (UCn-3), brain natriuretic peptide and prostacyclin synthase, wherein the said nucleic acid encoding a paracrine polypeptide or peptide is operably linked to a promoter, wherein the vector is an adeno-associated virus (AAV), and wherein the paracrine polypeptide or peptide is expressed in a cell.EFFECT: group of inventions provides treatment or improvement of CHF, diabetes or prediabetes in a patient.24 cl, 20 dwg, 3 tbl
eans for correction of psychoemotical status of organism based on astragalus herbs extract // 2642595
FIELD: pharmacology.SUBSTANCE: means for correction of the psychoemotional status of the organism, with antistress, antidepressant, anxiolytic and nootropic action, which is an aqueous or hydroalcoholic extract of Astragalus vulpinus Willd., containing flavonoids, ascorbic acid, saponins and tannins in a certain quantity.EFFECT: drug has a pronounced anti-stress, antidepressant, anxiolytic and nootropic effect, restores psychoemotional state of the organism.5 ex

Herbs-containing composition // 2642591
FIELD: pharmacology.SUBSTANCE: application of a combination of the following four components of plant origin: milkwort root; astragalus root; lovage root; and Angelica Sinensis root, in the manufacture of a medicament for treatment of a disease or disorder selected from the group consisting of stroke, neurological disorder or ischemia, or for neuroconditioning for prophylactic induction of cerebral tolerance to an ischemic, epileptic or other damaging event. A kit for application in a method for treatment of a disease or disorder selected from the group consisting of stroke, neurological disorder or ischemia, or for neuroconditioning for prophylactic induction of cerebral tolerance to an ischemic, epileptic or other damaging event. A composition for use in treatment of a disease or disorder selected from the group consisting of stroke, neurologic disorder, ischemia, or for neuroconditioning to ensure brain tolerance to an ischemic, epileptic or other damaging event.EFFECT: agents are effective for treatment of a disease or disorder selected from the group consisting of stroke, neurological disorder or ischemia, or for neuroconditioning for prophylactic induction of cerebral tolerance to an ischemic, epileptic or other damaging event.22 cl, 6 dwg, 3 ex
ethod of determining of excessive volume of eye socket's soft tissues for planning ophthalmocele correction operations // 2642543
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely ophthalmosurgery and maxillo-facial surgery, neurosurgery, ENT surgery, oncology, surgical dentistry, tectonic and reconstructive surgery, and can be used in the treatment of ophthalmocele. Dimension of eye socket’s soft tissues and part of eyeball are determined, located anteriorly from frontal plane, drawn through a straight line connecting two points most emerged from the topical right and left eye socket’s bars in the patient with ophthalmocele (Vex). Planning dimension of eye socket’s soft tissues and parts of eyeball are determined, located anteriorly from frontal plane, drawn through a straight line connecting two points most emerged from the topical right and left eye socket’s bars in the patient with ophthalmocele, which is necessary to retrieve in the result of performed operation (Vnormal). Individual excess volume of soft tissues (Vpathol) is calculated, which must be removed from the absconsio of bone-cutting of eye socket according to the original formula.EFFECT: method allows at preoperative stage objectively and quantitatively determine excess volume of soft tissues that need to be removed from the absconsio of bone-cutting of eye socket during decompression operation to correct the ophthalmocele, to minimize the risk of postoperative complications development by estimating the most significant parameters according to multi-layer spiral CT data.3 cl, 2 ex

Elastic absorbing composite material // 2642537
FIELD: human vital needs satisfaction.SUBSTANCE: invention relates to an absorbing composite material and an absorbing article including such an absorbing composite material. More particularly, the present invention relates to an absorbing composite material for use in hygienic absorbing articles such as sanitary napkins, daily pads, diapers, absorbing products for adults, etc.EFFECT: increased efficiency of products.15 cl, 14 dwg
ultifunctional quinoline derivatives as antineurodegenerative agents // 2642466
FIELD: chemistry.SUBSTANCE: invention relates to a hydroxy-derived quinoline of the formula (I) or to a pharmaceutically acceptable salt thereof, (I) wherein R1 is hydrogen, (C1-C3)alkyl, (C1)alkylene(C3)cycloalkyl, (C1)haloalkyl or (C1)alkylene(C6)aryl; R2 is hydrogen or halogen; R3 is hydrogen, halogen, (C1)alkyl or (C1)alkoxy; R4 is hydrogen, halogen, (C1)alkyl, (C1)alkoxy or (C1)haloalkyl; R5 and R6 are hydrogen; and R7 is (C9-C15)alkanol, (C1)alkylenepiperazinyl(C1-C2)alkanol, (C1-C8)alkylenepiperazinyl (C1-C2)alkyl, (C10-C13)alkylene OCOCH3, (C1)alkylene(C1)alkylamino(C3)alkynyl, (C1)alkyleneamino(C8)alkanol or (C1)alkyleneamino(C6)alkanol(C1)alkylene(8-methoxyquinolin-2-yl); or (II), where R1, R2, R3, R4 and R6 each is as described in (I) above; R5 is (C11-C12)alkanol, and R7 is hydrogen. The invention also relates to a pharmaceutical composition based on the formula (I) compounds, a method for treatment of Alzheimer's disease, traumatic brain injury and/or damage to the spinal cord and a method for improvement of the ability of learning and/or memory in a patient suffering from Alzheimer's disease, based on the formula (I) compound.EFFECT: new hydroxy derivatives of quinoline have been obtained that have useful biological properties.13 cl, 13 dwg, 9 ex
Cyclopropane carboxylate ethers of purine analogues // 2642463
FIELD: pharmacology.SUBSTANCE: invention relates to new cyclopropane carboxylate esters of purine analogues of the formula (T) or pharmaceutically acceptable salts thereof, which can be used for treatment of herpesvirus infections. Herpesvirus infection is an infection caused by the herpes simplex virus, infection of herpes zoster, or cytomegalovirus infection. In the compound of the formula (T) each Rx and Rz is independently hydrogen or (C1-C6)alkyl, or Rx is hydrogen and Rz is (C1-C6)alkyl, or Rx is (C1-C6)alkyl and Rz is hydrogen; and Ry is (C1-C6)alkyl, halo (C1-C6)alkyl, C6aryl, haloC6aryl or (C4-C5)heteroaryl with one heteroatom selected from nitrogen and oxygen in the ring.EFFECT: increased efficiency of compounds application.7 cl, 5 dwg, 3 tbl, 16 ex

Dysbiosis correction method of young farm livestock // 2642444
FIELD: veterinary medicine.SUBSTANCE: method consists in feeding the animal the food additive, containing the enzyme preparation, produced by the genetically unmodified micromycete culture with the high activity β-mannanase and probiotic Prolam, spread on kieselgur.EFFECT: invention usage will allow to form the microbiocenosis of the intestinal biotope and to increase the natural resistance of calves.1 tbl, 2 dwg, 3 ex
 
2550848.
Up!